Clinical cure of hepatitis B: consensus and controversy
10.3760/cma.j.cn501113-20200722-00409
- VernacularTitle:乙型肝炎临床治愈：共识与争议
- Author:
Jinlin HOU
1
;
Lai WEI
;
Guiqiang WANG
;
Jidong JIA
;
Zhongping DUAN
;
Hui ZHUANG
Author Information
1. 南方医科大学南方医院感染内科暨肝病中心，广州 510515
- Keywords:
Hepatitis B virus;
Treatment;
Clinical cure;
Functional cure
- From:
Chinese Journal of Hepatology
2020;28(8):636-639
- CountryChina
- Language:Chinese
-
Abstract:
Hepatitis B virus (HBV) infection is a serious global public health issue. At present, clinical cure is the ideal endpoint for hepatitis B treatment. That is to say, after the completion of treatment, the serum hepatitis B virus surface antigen (HBsAg) is negative, with or without the presence of antibody against hepatitis B virus surface antigen (anti-HBs), undetectable HBV DNA, liver biochemical indicators within normal range, and improved liver tissue lesions. However, it is difficult to achieve a satisfactory clinical cure effect based on the existing therapeutic drugs. To this end, scientists have conducted many explorations, whether it is a combination of nucleos(t)ide analogues and pegylated interferon therapy strategies, or timely termination of antiviral drug treatment, or accelerate the research and development of innovative drugs. The road to clinical cure of hepatitis B is obstructive and long, with full of opportunities and controversies, but the lead is about to come. We always believe that through unremitting efforts, the dream of helping chronic hepatitis B patients to obtain clinical cure or even complete cure will eventually come true.
